TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Merrimack Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
One Broadway, 14th Floor, Cambridge, MA, 02142, US
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
What was Merrimack Pharmaceuticals’s price range in the past 12 months?
Merrimack Pharmaceuticals lowest stock price was $3.56 and its highest was $9.45 in the past 12 months.
What is Merrimack Pharmaceuticals’s market cap?
Merrimack Pharmaceuticals’s market cap is $58.20M.
What is Merrimack Pharmaceuticals’s price target?
Currently, no data Available
What do analysts say about Merrimack Pharmaceuticals?
Not enough analysts have published a price target to provide an average price target.
When is Merrimack Pharmaceuticals’s upcoming earnings report date?
Merrimack Pharmaceuticals’s upcoming earnings report date is Nov 10, 2021 which is in 2 months.
How were Merrimack Pharmaceuticals’s earnings last quarter?
Merrimack Pharmaceuticals released its earnings results on Aug 05, 2021. The company reported -$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.057.
Is Merrimack Pharmaceuticals overvalued?
According to Wall Street analysts Merrimack Pharmaceuticals’s price is currently Overvalued.
Does Merrimack Pharmaceuticals pay dividends?
Merrimack Pharmaceuticals pays a Notavailable dividend of $0.5 which represents an annual dividend yield of 45.36%. Merrimack Pharmaceuticals’s last Notavailable dividend payment was on Dec 23, 2019. Merrimack Pharmaceuticals’s upcoming ex-dividend date is Dec 13, 2019
What is Merrimack Pharmaceuticals’s EPS estimate?
Merrimack Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Merrimack Pharmaceuticals have?
Merrimack Pharmaceuticals has 13,410,000 shares outstanding.
What happened to Merrimack Pharmaceuticals’s price movement after its last earnings report?
Merrimack Pharmaceuticals reported an EPS of -$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.879%.
Which hedge fund is a major shareholder of Merrimack Pharmaceuticals?
Currently, no hedge funds are holding shares in MACK